Synthesis, characterization, antiproliferative and molecular docking study of new half sandwich Ir(III), Rh(III) and Ru(II) complexes

Antibactericidal Ir(III) and Ru(II) Complexes with Phosphine-Alkaloid Conjugate and Their Interactions with Biomolecules: A Case of N-Methylphenethylamine

The phosphine ligand (Ph2 PCH2 N(CH3 )(CH2 )2 Ph, PNMPEA) obtained by the reaction of the (hydroxymethyl)diphenylphosphine with naturally occurring alkaloid N-methylphenethylamine, was used to synthesize the half-sandwich iridium(III) (Ir(η5 -Cp*)Cl2 Ph2 PCH2 N(CH3 )(CH2 )2 Ph, IrPNMPEA) and ruthenium(II) (Ru(η6 -p-cymene)Cl2 Ph2 PCH2 N(CH3 )(CH2 )2 Ph, RuPNMPEA) complexes. They were characterized using a vast array of methods, including 1D and 2D NMR, ESI(+)MS spectrometry, elemental analysis, cyclic voltammetry (CV), electron spectroscopy in the UV-Vis range (absorption, fluorescence) and density functional theory (DFT). The initial antimicrobial activity in vitro toward Gram-positive and Gram-negative bacterial strains was examined, indicating that both complexes are selective towards Gram-positive bacteria, e. g., Staphylococcus aureus, where the IrPNMPEA has been more bactericidal compared to RuPNMPEA. Additionally, the interactions of these compounds with various biomolecules, such as DNA (ctDNA, plasmid DNA, 9-ethylguanine (9-EtG), and 9-methyladenine (9-MeA)), nicotinamide adenine dinucleotide (NADH), glutathione (GSH), and ascorbic acid (Asc) were described. The results showed that both Ir(III) and Ru(II) complexes accelerate the oxidation process of NADH, GSH and Asc that appeared to occur by an electron transfer mechanism. Interestingly, only IrPNMPEA leads to the formation of various biomolecule adducts, which can explain its higher activity. Furthermore, RuPNMPEA and IrPNMPEA have been interacting with the DNA through weak noncovalent interactions.

Anticancer Half-Sandwich Rhodium(III) Complexes

Platinum-based anticancer drugs are most likely the most successful group of bioinorganic compounds. Their apparent disadvantages have led to the development of anticancer compounds of other noble metals, resulting in several ruthenium-based drugs which have entered clinical trials on oncological patients. Besides ruthenium, numerous rhodium complexes have been recently reported as highly potent antiproliferative agents against various human cancer cells, making them potential alternatives to Pt- and Ru-based metallodrugs. In this review, half-sandwich Rh(III) complexes are overviewed. Many representatives show higher in vitro potency than and different mechanisms of action (MoA) from the conventional anticancer metallodrugs (cisplatin in most cases) or clinically studied Ru drug candidates. Furthermore, some of the reviewed Rh(III) arenyl complexes are also anticancer in vivo. Pioneer anticancer organorhodium compounds as well as the recent advances in the field are discussed properly, and adequate attention is paid to their anticancer activity, solution behaviour and various processes connected with their MoA. In summary, this work summarizes the types of compounds and the most important biological results obtained in the field of anticancer half-sandwich Rh complexes.

DFT Investigation of the η6 ⇌ η6-Inter-ring Haptotropic Rearrangement of the Group 8 Metals Complexes [(graphene)MCp]+ (M = Fe, Ru, Os)

Metalcyclopentadienyl complexes (MCp)⁺ (M = Fe, Ru, Os) bound to the large polyaromatic hydrogenated hydrocarbon (PAH) C₉₆H₂₄ used as a model for pristine graphene have been studied using a density functional theory (DFT) generalized gradient approximation (PBE functional) to reveal their structural features and dynamic behavior. The inter-ring haptotropic rearrangements (IRHRs) for these complexes were shown to occur via two transition states and one intermediate. The energy barriers of the η⁶ ⇌ η⁶ IRHRs of the (MCp)⁺ unit were found to be 30, 27, and 29 kcal/mol for M = Fe, Ru, and Os, respectively. These values are significantly lower than the values found previously for smaller PAHs. Both polar and nonpolar solvents were found not to affect significantly the energy barrier heights. Investigated transition metal complexes could be used in general as catalysts in the design of novel derivatives or materials with promising properties. Metalcyclopentadienyl complexes (MCp)⁺ of PAHs show catalytic properties mainly due to their structural details as well as their important characteristic of inter-ring haptotropic rearrangement. IRHRs take place usually by intramolecular mechanisms. During IRHRs, the ML_n organometallic groups (OMGs) undergo shifting along the PAH plane and could coordinate additional reagents, which is important for catalysis. Large PAHs such as graphene, fullerenes, and nanotubes possess intrinsic anticancer activity, and numerous arene complexes of Ru and Os have been proven to have anticancer properties as well. We suppose that coordinating Ru or Os to very large PAHs could synergistically increase the anticancer activity of resulting complexes.

The interaction of half-sandwich (η5-Cp*)Rh(III) cation with histidine containing peptides and their ternary species with (N,N) bidentate ligands

Our goal was to explore the possible interactions of the potential metallodrug (η⁵-Cp*)Rh(III) complexes with histidine containing biomolecules (peptides/proteins) in order to understand the most important thermodynamic factors influencing the biospeciation and biotransformation of (η⁵-Cp*)Rh(III) complexes. To this end, here we report systematic solution thermodynamic and solution structural study on the interaction of (η⁵-Cp*)Rh(III) cation with histidine containing peptides and their constituents ((N-methyl)imidazole, GGA-OH, GGH-OH, histidine-amide, HGG-OH, GHG-NH₂), based on extensive ¹H NMR, ESI-MS and potentiometric investigations. The comparative evaluation of our data indicated that (η⁵-Cp*)Rh(III) cation is able to induce the deprotonation of amide nitrogen well below pH 7. Consequently, at physiological pH the peptides are coordinated to Rh(III) by tridentate manner, with the participation of amide nitrogen. At pH 7.4 the (η⁵-Cp*)Rh(III) binding affinity of peptides follow the order GGA-OH < < GGH-OH < < histidine-amide < HGG-OH < GHG-NH₂, i.e. the observed binding strength essentially depends on the presence and position of histidine within the peptide sequence. We also performed computational study on the possible solution structures of complexes present at near physiological pH. At pH 7.4 all histidine containing peptides form ternary complexes with strongly coordinating (N,N) bidentate ligands (ethylenediamine or bipyridyl), in which the peptides are monodentately coordinated to Rh(III) through their imidazole N¹‑nitrogens. In addition, the strongest chelators histidine-amide, HGG-OH and GHG-NH₂ are also able to displace these powerful bidentate ligands from the coordination sphere of Rh(III).

Crystal structure of chlorido-(η 5-pentamethylcyclopentadienyl)-(4-chloro-4-pyridyl-2,2′:6′,2′′-terpyridine-κ2N,N′) rhodium(III) hexaflourophosphate, C31H29Cl2F6N3PRh

C31H29Cl2F6N3PRh, monoclinic, P21/c (no. 14), a = 7.4069(7) Å, b = 13.245(1) Å, c = 32.141(3) Å, β = 93.924(2)°, V = 3145.8(5) Å3, Z = 4, R gt(F) = 0.0386, wR ref(F 2) = 0.0962, T = 123.15 K.

Cyclometalated Ir(III)-8-oxychinolin complexes acting as red-colored probes for specific mitochondrial imaging and anticancer drugs

A new class of luminescent Ir^III antitumor agents, namely, [Ir(CP1)(PY1)₂] (Ir-1), [Ir(CP1)(PY2)₂] (Ir-2), [Ir(CP1)(PY4)₂] (Ir-3), [Ir(CP2)(PY1)₂] (Ir-4), [Ir(CP2)(PY4)₂] (Ir-5), [Ir(CP3)(PY1)₂]⋅CH₃OH (Ir-6), [Ir(CP4)(PY4)₂]⋅CH₃OH (Ir-7), [Ir(CP5)(PY2)₂] (Ir-8), [Ir(CP5)(PY4)₂]⋅CH₃OH (Ir-9), [Ir(CP6)(PY1)₂] (Ir-10), [Ir(CP6)(PY2)₂]⋅CH₃OH (Ir-11), [Ir(CP6)(PY3)₂] (Ir-12), [Ir(CP6)(PY41)₂] (Ir-13), and [Ir(CP7)(PY1)₂] (Ir-14), supported by 8-oxychinolin derivatives and 1-phenylpyrazole ligands was prepared. Compared with SK-OV-3/DDP and HL-7702 cells, the Ir-1-Ir-14 compounds exhibited half maximal inhibitory concentration (IC₅₀) values within the high nanomolar range (50 nM-10.99 μM) in HeLa cells. In addition, Ir-1 and Ir-3 accumulated and stained the mitochondrial inner membrane of HeLa cells with high selectivity and exhibited a high antineoplastic activity in the entire cervical HeLa cells, with IC₅₀ values of 1.22 ± 0.36 μM and 0.05 ± 0.04 μM, respectively. This phenomenon induced mitochondrial dysfunction, suggesting that these cyclometalated Ir^III complexes can be potentially used in biomedical imaging and Ir(III)-based anticancer drugs. Furthermore, the high cytotoxicity activity of Ir-3 is correlated with the 1-phenylpyrazole (H-PY4) secondary ligands in the luminescent Ir^III antitumor complex.

Crystal structure of chlorido-(η 5-pentamethylcyclopentadienyl)-((bis-pyrazol-1-yl)methane-κ2 N,N′) rhodium(III) hexafluorophosphate. (C17H23ClN4RhF6P)

C17H23ClN4RhF6P, monoclinic, P21/c (no. 14), a = 10.6954(2) Å, b = 15.3868(3) Å, c = 12.6130(2) Å, β = 90.5590(10)°, V = 2075.60(7) Å3, Z = 4, R gt(F) = 0.0296, wR ref(F 2) = 0.0727, T = 100(2) K.

Crystal structure of η6-p-cymene-iodido-(N-isopropyl-1-(pyridin-2-yl)methanimine-κ2 N,N′)ruthenium(II) hexafluorophosphate(V), C19H26IN2F6Ru

C19H26IN2F6Ru, triclinic, P1̄ (no. 2), a = 9.240(2) Å, b = 10.019(3) Å, c = 12.689(3) Å, α = 78.921°, β = 81.596(10)°, γ = 83.654°, V = 1136.30(5) Å3, Z = 2, R gt(F) = 0.0174, wR ref(F 2) = 0.0440, T = 173 K.

Crystal structure of (E)-N-(4-chlorophenyl)-1-(pyridin-2-yl)methanimine, C12H9ClN2

C12H9ClN2, monoclinic, P21/c (no. 14), a = 19.0184(3) Å, b = 4.81220(10) Å, c = 11.3896(2) Å, β = 107.388(1)°, Z = 4, V = 994.75(3) Å3, R gt(F) = 0.0284, wR ref(F 2) = 0.0800, T = 100(2) K.

Organometallic Conjugates of the Drug Sulfadoxine for Combatting Antimicrobial Resistance

Fourteen novel arene Ru^II , and cyclopentadienyl (Cp^x ) Rh^III and Ir^III complexes containing an N,N'-chelated pyridylimino- or quinolylimino ligand functionalized with the antimalarial drug sulfadoxine have been synthesized and characterized, including three by X-ray crystallography. The rhodium and iridium complexes exhibited potent antiplasmodial activity with IC₅₀ values of 0.10-2.0 μm in either all, or one of the three Plasmodium falciparum assays (3D7 chloroquine sensitive, Dd2 chloroquine resistant and NF54 sexual late stage gametocytes) but were only moderately active towards Trichomonas vaginalis. They were active in both the asexual blood stage and the sexual late stage gametocyte assays, whereas the clinical parent drug, sulfadoxine, was inactive. Five complexes were moderately active against Mycobacterium tuberculosis (IC₅₀ <6.3 μm), while sulfadoxine showed no antitubercular activity. An increase in the size of both the Cp^x ligand and the aromatic imino substituent increased hydrophobicity, which resulted in an increase in antiplasmodial activity.

Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium

A summary of recent developments on the anticancer activity of complexes of rhenium, osmium, and iridium is described.

A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?

In this minireview, we refer to recent results as far as the Platelet Activating Factor (PAF) inhibitors are concerned. At first, results of organic compounds (natural and synthetic ones and specific and nonspecific) as inhibitors of PAF are reported. Emphasis is given on recent results about a new class of the so-called metal-based inhibitors of PAF. A small library of 30 metal complexes has been thus created; their anti-inflammatory activity has been further evaluated owing to their inhibitory effect against PAF in washed rabbit platelets (WRPs). In addition, emphasis has also been placed on the identification of preliminary structure-activity relationships for the different classes of metal-based inhibitors.

Crystal structure of chlorido-(N-(2,5-dichlorophenyl)-1-(pyridin-2-yl)methanimine-κ2 N,N′)(η 6-1-isopropyl-4-methyl benzene) ruthenium (II) tetrafluoroborate, C22H22Cl3N2BF4Ru

C22H22Cl3N2BF4Ru, monoclinic, P21/n (no. 14), a = 15.067(5) Å, b = 10.409(5) Å, c = 16.503(5) Å, β = 112.75(5)°, V = 2386.9(16) Å3, Z = 4, R gt(F) = 0.0211, wR ref(F 2) = 0.0535, T = 173 K.

Half-sandwich iridium N-heterocyclic carbene anticancer complexes

Half-sandwich iridium N-heterocyclic carbene complexes display potent anticancer activities and are attractive for development as new anticancer agents.